Regulation of inducible Nitric Oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 153-163

  Soskić, Sanja S ^a   Dobutović, Branislava D ^a   Sudar, Emina M ^a   Obradović, Milan M ^a   Nikolić, Dragana M ^b   Radak, Djordje J ^c   Mikhailidis, Dimitri P ^d   Isenović, Esma R ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes; Heart failure; Inducible nitric oxide synthase; Insulin resistance

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GHRELIN RECEPTOR; GLITAZONE DERIVATIVE; GLUTATHIONE PEROXIDASE; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N6 (1 IMINOETHYL)LYSINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C BETA; RUBOXISTAURIN; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; UNINDEXED DRUG;

ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME REGULATION; HEART FAILURE; HUMAN; INSULIN RESISTANCE; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 80053525165     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010153     Document Type: Review

References (175)

1. Pautz A, Art J, Hahn S, et al. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010; 23: 75-93.
2. Forstermann U, Li H, Schwarz P, Kleinert H. NO Synthesis and NOS regulation. In: Forman H, Fukuto J, Torres M, Eds. Signal Transduction by Reactive Oxygen and Nitrogen Species: Pathways and Chemical Principles: Springer Netherlands 2004; pp. 119-154.
3. Zhang P, Xu X, Hu X, et al. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007; 100: 1089-1098.
4. Sudar E, Dobutovic B, Soskic S, et al. Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelintreated rats. J Physiol Biochem 2010.
5. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20: 298-303.
6. Sekiguchi F, Miyake Y, Hirakawa A, et al. Hypertension and impairment of endothelium-dependent relaxation of arteries from spontaneously hypertensive and L-NAME-treated Wistar rats. J Smooth Muscle Res 2001; 37: 67-79.
7. Isenovic ER, Meng Y, Divald A, Milivojevic N, Sowers JR. Role of phosphatidylinositol 3-kinase/Akt pathway in angiotensin II and insulin-like growth factor-1 modulation of nitric oxide synthase in vascular smooth muscle cells. Endocrine 2002; 19: 287-292.
8. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 2000; 275: 715-719.
9. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-350.
10. Fujimoto M, Shimizu N, Kunii K, et al. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 2005; 54: 1340-1348.
11. LaPointe MC, Isenovic E. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 1999; 33: 276-282.
12. Lee JH, Palaia T, Ragolia L. Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation. Am J Physiol Cell Physiol 2009; 296: C327-338.
13. Nagareddy PR, Soliman H, Lin G, et al. Selective inhibition of protein kinase C beta(2) attenuates inducible nitric oxide synthasemediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. Diabetes 2009; 58: 2355-2364.
14. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
15. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-11063.
16. Xia Z, Kuo KH, Nagareddy PR, et al. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 2007; 73: 770-782.
17. Lin G, Liu Y, MacLeod KM. Regulation of muscle creatine kinase by phosphorylation in normal and diabetic hearts. Cell Mol Life Sci 2009; 66: 135-144.
18. Heusch P, Aker S, Boengler K, et al. Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation. Am J Physiol Heart Circ Physiol 2010; 299: H446-453.
19. Dias FA, Urboniene D, Yuzhakova MA, et al. Ablation of iNOS delays cardiac contractile dysfunction in chronic hypertension. Front Biosci (Elite Ed) 2010; 2: 312-324.
20. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006; 213-254.
21. Hibbs JB, Taintor RR, Vavrin Z, et al. Synthesis of nitric oxide from a terminal guanidine nitrogen atom of l-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. Amsterdam: Elsevier 1990.
22. Morris SM, Jr., Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994; 266: E829-839.
23. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131.
24. Santolini J, Meade AL, Stuehr DJ. Differences in three kinetic parameters underpin the unique catalytic profiles of nitric-oxide synthases I, II, and III. J Biol Chem 2001; 276: 48887-48898.
25. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78: 915-918.
26. Isenovic E, LaPointe MC. Role of Ca(2+)-independent phospholipase A(2) in the regulation of inducible nitric oxide synthase in cardiac myocytes. Hypertension 2000; 35: 249-254.
27. Sudar E, Velebit J, Gluvic Z, et al. Hypothetical mechanism of sodium pump regulation by estradiol under primary hypertension. J Theor Biol 2008; 251: 584-592.
28. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995; 80: 199-211.
29. Minden A, Lin A, McMahon M, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994; 266: 1719-1723.
30. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-267.
31. Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinasegamma. J Biol Chem 1998; 273: 19080-19085.
32. Hausel P, Latado H, Courjault-Gautier F, Felley-Bosco E. Srcmediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase. Oncogene 2006; 25: 198-206.
33. Closs EI, Scheld JS, Sharafi M, Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 2000; 57: 68-74.
34. Wu J, Lin Q, Lu Y, Willis WD, Westlund KN. Changes in nitric oxide synthase isoforms in the spinal cord of rat following induction of chronic arthritis. Exp Brain Res 1998; 118: 457-465.
35. El-Gayar S, Thuring-Nahler H, Pfeilschifter J, Rollinghoff M, Bogdan C. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages. J Immunol 2003; 171: 4561-4568.
36. Hecker M, Preifl C, Stockhausen H, et al. Different mechanism are involved in the inhibition of nitric oxide synthase expression by anti-oxidants in cytokine-stimulated macrophages1995
37. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 2007; 137: 1616S-1620S.
38. Forstermann U, Gath I, Schwarz P, Closs EI, Kleinert H. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol 1995; 50: 1321-1332.
39. Tzeng E, Billiar TR, Robbins PD, Loftus M, Stuehr DJ. Expression of human inducible nitric oxide synthase in a tetrahydrobiopterin (H4B)-deficient cell line: H4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci USA 1995; 92: 11771-11775.
40. Ionova IA, Vasquez-Vivar J, Whitsett J, et al. Deficient BH4 production via de novo and salvage pathways regulates NO responses to cytokines in adult cardiac myocytes. Am J Physiol Heart Circ Physiol 2008; 295: H2178-2187.
41. Muhl H, Pfeilschifter J. Tetrahydrobiopterin is a limiting factor of nitric oxide generation in interleukin 1 beta-stimulated rat glomerular mesangial cells. Kidney Int 1994; 46: 1302-1306.
42. Ratovitski EA, Alam MR, Quick RA, et al. Kalirin inhibition of inducible nitric-oxide synthase. J Biol Chem 1999; 274: 993-999.
43. Ratovitski EA, Bao C, Quick RA, et al. An inducible nitric-oxide synthase (NOS)-associated protein inhibits NOS dimerization and activity. J Biol Chem 1999; 274: 30250-30257.
44. Jones RJ, Jourd'heuil D, Salerno JC, Smith SM, Singer HA. iNOS regulation by calcium/calmodulin-dependent protein kinase II in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2007; 292: H2634-642.
45. Knowles RG, Salter M, Brooks SL, Moncada S. Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun 1990; 172: 1042-1048.
46. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87: 10043-10047.
47. Fukuchi M, Giaid A. Endothelial expression of endothelial nitric oxide synthase and endothelin-1 in human coronary artery disease. Specific reference to underlying lesion. Lab Invest 1999; 79: 659-670.
48. Wilcox JN, Subramanian RR, Sundell CL, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17: 2479-2488.
49. Azadzoi KM, Master TA, Siroky MB. Effect of chronic ischemia on constitutive and inducible nitric oxide synthase expression in erectile tissue. J Androl 2004; 25: 382-388.
50. Kim JW, Kang KW, Oh GT, et al. Induction of hepatic inducible nitric oxide synthase by cholesterol in vivo and in vitro. Exp Mol Med 2002; 34: 137-144.
51. Aliev G, Bodin P, Burnstock G. Free radical generators cause changes in endothelial and inducible nitric oxide synthases and endothelin-1 immunoreactivity in endothelial cells from hyperlipidemic rabbits. Mol Genet Metab 1998; 63: 191-197.
52. Bu DX, Erl W, de Martin R, Hansson GK, Yan ZQ. IKKbetadependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia. FASEB J 2005; 19: 1293-1295.
53. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000; 20: E83-88.
54. Ginnan R, Guikema BJ, Halligan KE, Singer HA, Jourd'heuil D. Regulation of smooth muscle by inducible nitric oxide synthase and NADPH oxidase in vascular proliferative diseases. Free Radic Biol Med 2008; 44: 1232-1245.
55. Hecker M, Cattaruzza M, Wagner AH. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen Pharmacol 1999; 32: 9-16.
56. Jiang B, Xu S, Hou X, et al. Temporal control of NF-kappaB activation by ERK differentially regulates interleukin-1betainduced gene expression. J Biol Chem 2004; 279: 1323-1329.
57. Beraud C, Henzel WJ, Baeuerle PA. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 1999; 96: 429-434.
58. Bitar MS, Ayed AK, Abdel-Halim SM, Isenovic ER, Al-Mulla F. Inflammation and apoptosis in aortic tissues of aged type II diabetes: amelioration with alpha-lipoic acid through phosphatidylinositol 3- kinase/Akt- dependent mechanism. Life Sci 2010; 86: 844-853.
59. Da Silva J, Pierrat B, Mary JL, Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitricoxide synthase expression in mouse astrocytes. J Biol Chem 1997; 272: 28373-28380.
60. Hua LL, Zhao ML, Cosenza M, et al. Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNFalpha expression in human fetal astrocytes. J Neuroimmunol 2002; 126: 180-189.
61. Jiang B, Xu S, Brecher P, Cohen RA. Growth factors enhance interleukin-1 beta-induced persistent activation of nuclear factorkappa B in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2002; 22: 1811-1816.
62. Xu S, Bayat H, Hou X, Jiang B. Ribosomal S6 kinase-1 modulates interleukin-1beta-induced persistent activation of NF-kappaB through phosphorylation of IkappaBbeta. Am J Physiol Cell Physiol 2006; 291: C1336-1345.
63. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
64. Kim J, Song G, Gao H, et al. Insulin-like growth factor II activates phosphatidylinositol 3-kinase-protooncogenic protein kinase 1 and mitogen-activated protein kinase cell Signaling pathways, and stimulates migration of ovine trophectoderm cells. Endocrinology 2008; 149: 3085-3094.
65. Elizalde M, Ryden M, van Harmelen V, et al. Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J Lipid Res 2000; 41: 1244-1251.
66. Shimabukuro M, Higa M, Zhou YT, et al. Lipoapoptosis in betacells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998; 273: 32487-32490.
67. Ceriello A, Quagliaro L, D'Amico M, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 2002; 51: 1076-1082.
68. Sharma K, Danoff TM, DePiero A, Ziyadeh FN. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem Biophys Res Commun 1995; 207: 80-88.
69. Sugita H, Kaneki M, Tokunaga E, et al. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab 2002; 282: E386-394.
70. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994; 269: 4705-4708.
71. Haidara MA, Yassin HZ, Zakula Z, Mikhailidis DP, Isenovic ER. Diabetes and antioxidants: myth or reality? Curr Vasc Pharmacol 2010; 8: 661-672.
72. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001; 7: 1138-1143.
73. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784-1789.
74. Torres SH, De Sanctis JB, de LBM, Hernandez N, Finol HJ. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol 2004; 181: 419-427.
75. Tannous M, Rabini RA, Vignini A, et al. Evidence for iNOSdependent peroxynitrite production in diabetic platelets. Diabetologia 1999; 42: 539-544.
76. Bedard S, Marcotte B, Marette A. Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem J 1997; 325 (Pt 2): 487-493.
77. Dobashi K, Asayama K, Nakane T, et al. Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. Life Sci 2000; 67: 2093-2101.
78. Maggi LB, Jr., Sadeghi H, Weigand C, et al. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 2000; 49: 346-355.
79. Da Ros R, Assaloni R, Ceriello A. The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 2004; 21: 1249-1252.
80. Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 2004; 279: 20767-20774.
81. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-1677.
82. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.
83. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-446.
84. Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105: 199-205.
85. Kubota N, Tobe K, Terauchi Y, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000; 49: 1880-1889.
86. Valverde AM, Burks DJ, Fabregat I, et al. Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes 2003; 52: 2239-2248.
87. Suzuki R, Tobe K, Aoyama M, et al. Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice. J Biol Chem 2004; 279: 25039-25049.
88. Shimomura I, Matsuda M, Hammer RE, et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000; 6: 77-86.
89. Kerouz NJ, Horsch D, Pons S, Kahn CR. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 1997; 100: 3164-3172.
90. Anai M, Funaki M, Ogihara T, et al. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 1998; 47: 13-23.
91. Kim F, Pham M, Maloney E, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1982-1988.
92. Rizzo NO, Maloney E, Pham M, et al. Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. Arterioscler Thromb Vasc Biol 2010; 30: 758-765.
93. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27(Suppl 3): S49-52.
94. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
95. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 2005; 25: 989-994.
96. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27(Suppl 3): S53-55.
97. Charbonneau A, Marette A. Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins. Diabetes 2010; 59: 861-871.
98. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
99. Carvalho-Filho MA, Ueno M, Hirabara SM, et al. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 2005; 54: 959-967.
100. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006; 6: 177-181.
101. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 2005; 54: 1082-1089.
102. Kapur S, Bedard S, Marcotte B, Cote CH, Marette A. Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes 1997; 46: 1691-1700.
103. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)- associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-50236.
104. Park E, Wong V, Guan X, Oprescu AI, Giacca A. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J Endocrinol 2007; 195: 323-331.
105. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008; 8: 923-934.
106. Pacher P, Obrosova IG, Mabley JG, Szabo C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 2005; 12: 267-275.
107. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
108. Yang P, Cao Y, Li H. Hyperglycemia induces inducible nitric oxide synthase gene expression and consequent nitrosative stress via c-Jun N-terminal kinase activation. Am J Obstet Gynecol 2010; 203: 185 e5-11.
109. Yang P, Zhao Z, Reece EA. Activation of oxidative stress signaling that is implicated in apoptosis with a mouse model of diabetic embryopathy. Am J Obstet Gynecol 2008; 198: 130 e1-7.
110. Yang P, Zhao Z, Reece EA. Blockade of c-Jun N-terminal kinase activation abrogates hyperglycemia-induced yolk sac vasculopathy in vitro. Am J Obstet Gynecol 2008; 198: 321 e1-7.
111. Yang P, Zhao Z, Reece EA. Involvement of c-Jun N-terminal kinases activation in diabetic embryopathy. Biochem Biophys Res Commun 2007; 357: 749-754.
112. Nath AK, Enciso J, Kuniyasu M, et al. Nitric oxide modulates murine yolk sac vasculogenesis and rescues glucose induced vasculopathy. Development 2004; 131: 2485-2496.
113. Forrester K, Ambs S, Lupold SE, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996; 93: 2442-7.
114. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 1999; 5: 90-6.
115. Bennett M, Macdonald K, Chan SW, et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290-3.
116. Zakula Z, Koricanac G, Putnikovic B, Markovic L, Isenovic ER. Regulation of the inducible nitric oxide synthase and sodium pump in type 1 diabetes. Med Hypotheses 2007; 69: 302-6.
117. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-46.
118. Litwin SE, Raya TE, Anderson PG, Daugherty S, Goldman S. Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J Clin Invest 1990; 86: 481-8.
119. Rubler S, Sajadi RM, Araoye MA, Holford FD. Noninvasive estimation of myocardial performance in patients with diabetes. Effect of alcohol administration. Diabetes 1978; 27: 127-34.
120. Ren J, Walsh MF, Hamaty M, Sowers JR, Brown RA. Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca2+ and NO. Am J Physiol 1998; 275: H823-30.
121. Ren J, Sowers JR, Walsh MF, Brown RA. Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol 2000; 279: H1708-14.
122. Walsh MF, Ali SS, Sowers JR. Vascular insulin/insulin-like growth factor-1 resistance in female obese Zucker rats. Metabolism 2001; 50: 607-12.
123. Tirupattur PR, Ram JL, Standley PR, Sowers JR. Regulation of Na+,K(+)-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens 1993; 6: 626-9.
124. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
125. Yan Z, Hansson GK. Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ Res 1998; 82: 21-9.
126. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999; 43: 650-7.
127. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1993; 90: 3491-5.
128. Ward ME, Toporsian M, Scott JA, et al. Hypoxia induces a functionally significant and translationally efficient neuronal NO synthase mRNA variant. J Clin Invest 2005; 115: 3128-3139.
129. Papadaki M, Tilton RG, Eskin SG, McIntire LV. Nitric oxide production by cultured human aortic smooth muscle cells: stimulation by fluid flow. Am J Physiol 1998; 274: H616-26.
130. Nakata S, Tsutsui M, Shimokawa H, et al. Vascular neuronal NO synthase is selectively upregulated by platelet-derived growth factor: involvement of the MEK/ERK pathway. Arterioscler Thromb Vasc Biol 2005; 25: 2502-2508.
131. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87: 5193-5197.
132. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655.
133. Isenovic E, Muniyappa R, Milivojevic N, Rao Y, Sowers JR. Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity. Biochem Biophys Res Commun 2001; 285: 954-958.
134. Hansson GK, Geng YJ, Holm J, et al. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994; 180: 733-738.
135. Miyoshi T, Li Y, Shih DM, et al. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice. Life Sci 2006; 79: 525-531.
136. Aker S, Snabaitis AK, Konietzka I, et al. Inhibition of the Na+/H+ exchanger attenuates the deterioration of ventricular function during pacing-induced heart failure in rabbits. Cardiovasc Res 2004; 63: 273-282.
137. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol 1998; 30: 1215-1223.
138. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93: 1087-1094.
139. Fukuchi M, Hussain SN, Giaid A. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in endstage human heart failure: their relation to lesion site and betaadrenergic receptor therapy. Circulation 1998; 98: 132-139.
140. Liao X, Liu JM, Du L, et al. Nitric oxide signaling in stretchinduced apoptosis of neonatal rat cardiomyocytes. FASEB J 2006; 20: 1883-1885.
141. Rastaldo R, Pagliaro P, Cappello S, et al. Nitric oxide and cardiac function. Life Sci 2007; 81: 779-793.
142. Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005; 108: 225-256.
143. Otani H. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal 2009; 11: 1913-1928.
144. Ziolo MT, Katoh H, Bers DM. Expression of inducible nitric oxide synthase depresses beta-adrenergic-stimulated calcium release from the sarcoplasmic reticulum in intact ventricular myocytes. Circulation 2001; 104: 2961-2966.
145. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 2002; 105: 236-243.
146. Funakoshi H, Kubota T, Kawamura N, et al. Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res 2002; 90: 959-965.
147. Post H, Schulz R, Gres P, Heusch G. No involvement of nitric oxide in the limitation of beta-adrenergic inotropic responsiveness during ischemia. Am J Physiol Heart Circ Physiol 2001; 281: H2392-2397.
148. Gallo MP, Malan D, Bedendi I, et al. Regulation of cardiac calcium current by NO and cGMP-modulating agents. Pflugers Arch 2001; 441: 621-628.
149. Kelm M, Schafer S, Dahmann R, et al. Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generation. Cardiovasc Res 1997; 36: 185-194.
150. Heusch G, Post H, Michel MC, Kelm M, Schulz R. Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res 2000; 87: 146-152.
151. Davidson SM, Duchen MR. Effects of NO on mitochondrial function in cardiomyocytes: Pathophysiological relevance. Cardiovasc Res 2006; 71: 10-21.
152. Chen Y, Traverse JH, Du R, Hou M, Bache RJ. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 2002; 106: 273-279.
153. Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 2005; 106: 147-162.
154. Andreka P, Tran T, Webster KA, Bishopric NH. Nitric oxide and promotion of cardiac myocyte apoptosis. Mol Cell Biochem 2004; 263: 35-53.
155. Heger J, Godecke A, Flogel U, et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 2002; 90: 93-99.
156. Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002; 109: 735-743.
157. Wunderlich C, Flogel U, Godecke A, Heger J, Schrader J. Acute inhibition of myoglobin impairs contractility and energy state of iNOS-overexpressing hearts. Circ Res 2003; 92: 1352-1358.
158. Wang WW, Jenkinson CP, Griscavage JM, et al. Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide. Biochem Biophys Res Commun 1995; 210: 1009-1016.
159. Zunic G, Supic G, Magic Z, Draskovic B, Vasiljevska M. Increased nitric oxide formation followed by increased arginase activity induces relative lack of arginine at the wound site and alters whole nutritional status in rats almost within the early healing period. Nitric Oxide 2009; 20: 253-258.
160. Wells SM, Holian A. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol 2007; 36: 520-528.
161. Canton M, Neverova I, Menabo R, Van Eyk J, Di Lisa F. Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. Am J Physiol Heart Circ Physiol 2004; 286: H870-877.
162. Canton M, Skyschally A, Menabo R, et al. Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur Heart J 2006; 27: 875-881.
163. White AR, Ryoo S, Li D, et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2006; 47: 245-251.
164. Zhang C, Hein TW, Wang W, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004; 44: 935-943.
165. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996; 79: 363-380.
166. Ziolo MT, Maier LS, Piacentino V, 3rd, et al. Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation 2004; 109: 1886-1891.
167. Yamamoto S, Tsutsui H, Tagawa H, et al. Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Circulation 1997; 95: 1111-1114.
168. Mungrue IN, Husain M, Stewart DJ. The role of NOS in heart failure: lessons from murine genetic models. Heart Fail Rev 2002; 7: 407-422.
169. Ide T, Tsutsui H, Kinugawa S, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 2000; 86: 152-157.
170. Liu YH, Carretero OA, Cingolani OH, et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2005; 289: H2616-2623.
171. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280: C53-60.
172. Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2004; 109: 544-549.
173. Takimoto E, Champion HC, Li M, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115: 1221-1231.
174. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002; 90: 21-28.
175. Rassaf T, Bryan NS, Maloney RE, et al. NO adducts in mammalian red blood cells: too much or too little? Nat Med 2003; 9: 481-482; author reply 2-3.